A senior executive at Credit Suisse Taiwan Elsa Chiu and her husband were released on bail early Wednesday after being interrogate about alleged insider trading in the takeover of Hermes Microvision by ASML of the Netherlands, Taipei District Prosecutors Office spokesman Chang Chieh-Chin told Reuters.
"During the merger and acquisition activities, there were some trading irregularities, and the stock exchange regulator detected this irregular trading," said Chang, who is also a deputy chief prosecutor.
French drugmaker Sanofi and Swiss manufacturer Lonza, a supplier to the pharmaceutical, healthcare and life-science industries, announced Monday that they have entered into a strategic partnership to establish a large-scale biologics production facility in Switzerland. The initial investment will be around 290 million Swiss francs (€270 million), to be split equally between each company.
Pending regulatory approvals, the facility, through a 50-50 joint venture, will be located in Visp, Switzerland, Sanofi and Lonza said in a joint statement. The initial phase of the facility will commence construction in 2017, it is expected to be fully operational by 2020.
PSA Group is discussing a potential acquisition of rival European carmaker Opel from General Motors, a spokesman for the French automaker said on Tuesday.
"PSA confirms that it is exploring a number of strategic initiatives with GM with the aim of increasing its profitability and operating efficiency, including a potential acquisition of Opel," company spokesman Bertrand Blaise said.
Lastminute.com strengthens its presence in Italy by signing agreement with Travel Holding to acquire Gartour, an italian leading incoming tour operator. The latter, according to the agreements made by the parties, will continue its activities under a renewable contract of lease for a period of twelve months, before passing definitively under Lastminute.com. Gartour currently employs about 130 people for a turnover of €35 million in 2016.
Swiss pesticides and seeds group Syngenta reported 2016 earnings before interest, tax, depreciation and amortisation (EBITDA) of $2.66 billion on sales of $12.79 billion.
Analysts polled by Reuters had on average expected EBITDA to fall 5.9 percent to $2.61 billion on sales down 4.2 percent to $12.85 billion. They had expected it to boost its dividend to 11.60 Swiss francs from 11.00
Johnson & Johnson will buy Swiss drugmaker Actelion in a $30 billion deal that both secures promising research and bolsters the product portfolio controlled by the U.S. health care giant.
The deal between the world’s biggest producer of healthcare goods and Actelion, a leader in medicines treating high blood pressure, will create a new Swiss-listed firm called R&D NewCo focusing on the research and development of new drugs, the two companies said in a joint statement.
The U.S. conglomerate will then buy Actelion’s seven drugs that are currently on the market and two potential treatments in late-stage testing. The acquisition gives J&J access to the Swiss group’s line-up of high-price, high-margin medicines for rare diseases, helping it diversify its drug portfolio as its biggest product.
Yahoo says its closing its Verizon deal in the second quarter instead of in the first quarter, which is when it initially said the deal would close. The $4.8 billion deal was originally slated to close in the first quarter, but that was before Yahoo reported two massive data breaches that analysts say may scrap the entire deal.
Although Yahoo continues to work to close the acquisition, there’s still work required to meet closing the deal’s closing conditions, the company said in an earnings statement, without elaborating.
MasterCard has put forward proposals to the Competition and Markets Authority (CMA) after the watchdog expressed concern over its acquisition of VocaLink. The CMA said the merger could make it difficult for the UK ATM network Link to negotiate a good infrastructure service because of reduced competition.
The CMA had given MasterCard and VocaLink an ultimatum to remedy its competition concerns or face an in-depth investigation.
For qualified investors / professional clients only
In order to proceed, you must confirm that you are a qualified investor based in Switzerland
The information contained in this section have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith, but is not guaranteed as being accurate, nor is it a complete statement or summary of the securities, markets or developments referred to in the document.
Before investing in a product please read the latest prospectus carefully and thoroughly and note that funds mentioned herein may not be eligible for sale in all jurisdictions or to certain categories of investors The information mentioned herein is not intended to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. Past performance is not a reliable indicator of future results. The performance shown does not take account of any commissions and costs charged when subscribing to and redeeming units. Commissions and costs have a negative impact on performance. If the currency of a financial product or financial service is different from your reference currency, the return can increase or decrease as a result of currency fluctuations. This information pays no regard to the specific or future investment objectives, financial or tax situation or particular needs of any specific recipient. The details and opinions contained in this document are provided without any guarantee or warranty and are for the recipient's personal use and information purposes only
